regulatory
confidence high
sentiment positive
materiality 0.50
Erasca receives FDA Fast Track Designation for naporafenib combo in NRAS-mutant melanoma
Erasca, Inc.
- FDA granted Fast Track Designation to naporafenib + trametinib for unresectable/metastatic NRASm melanoma after PD-(L)1 failure.
- FTD facilitates development and expedites review for drugs addressing unmet medical needs.
- Benefits include more frequent FDA interactions and potential rolling submission of marketing application.
- Naporafenib (ERAS-007) is an oral pan-RAF inhibitor; trametinib is a MEK inhibitor already marketed as MEKINIST.